Issues
-
Cover Image
Cover Image
Evasion from immune recognition contributes to tumor growth. Stagg and colleagues have recently identified CD73 expression on tumor cells as an important mechanism of tumor immune evasion. The cover image represents CD73 expression (green) detected by immunofluorescence on MDA-MB-231 breast cancer cells. Stagg and colleagues describe that CD73 expression on hematopoietic and nonhematopoietic host cells also contributes to tumor immune evasion. Using adoptive reconstitution of T regulatory cells (Treg), their study defines CD73 as an important immunosuppressive factor expressed by Treg that promotes tumor growth. Their study also reveals that nonhematopoietic expression of CD73, possibly on endothelial cells, enhances metastasis of circulating tumor cells. Finally, they report that anti-CD73 therapy inhibits the growth and metastatic potential of CD73-negative tumor cells. Taken together, their study suggests that CD73 may be targeted at multiple levels to induce anticancer effects. For details, see the article by Stagg and colleagues on page 2892 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Priority Report
Integrated Systems and Technologies
Microenvironment and Immunology
A Critical Role for GRP78/BiP in the Tumor Microenvironment for Neovascularization during Tumor Growth and Metastasis
Enhanced Efficacy of Therapeutic Cancer Vaccines Produced by Co-Treatment with Mycobacterium tuberculosis Heparin-Binding Hemagglutinin, a Novel TLR4 Agonist
Molecular and Cellular Pathobiology
FLT3-Mediated p38–MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis
The Neuronal Differentiation Factor NeuroD1 Downregulates the Neuronal Repellent Factor Slit2 Expression and Promotes Cell Motility and Tumor Formation of Neuroblastoma
Prevention and Epidemiology
Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions
Therapeutics, Targets, and Chemical Biology
PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Tumor and Stem Cell Biology
Frizzled 4 Regulates Stemness and Invasiveness of Migrating Glioma Cells Established by Serial Intracranial Transplantation
EMT and Stem Cell–Like Properties Associated with miR-205 and miR-200 Epigenetic Silencing Are Early Manifestations during Carcinogen-Induced Transformation of Human Lung Epithelial Cells
Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth
CAMTA1, a 1p36 Tumor Suppressor Candidate, Inhibits Growth and Activates Differentiation Programs in Neuroblastoma Cells
Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.